Direct oral anticoagulants in hypercoagulable states

Area of Science:

• Cardiology
• Hematology
• Pharmacology

Background:

• Direct oral anticoagulants (DOACs) are established for venous thromboembolism.
• Their efficacy and safety in hypercoagulable states like heparin-induced thrombocytopenia (HIT) and antiphospholipid syndrome (APS) remain uncertain.
• Warfarin, a traditional anticoagulant, has limitations including a narrow therapeutic window and drug/food interactions.

Purpose of the Study:

• To evaluate the safety and efficacy of apixaban and rivaroxaban in patients with definite HIT or APS.
• To explore the use of DOACs as alternatives for patients intolerant or refractory to warfarin.

Main Methods:

• Retrospective analysis of 23 patients with definite HIT (12) or APS (11) treated with apixaban or rivaroxaban.
• Data collected included clinico-pathologic features, efficacy (recurrent thrombosis), and safety (bleeding events).
• Median follow-up was 7 months (range 2-39 months).

Main Results:

• Zero patients experienced recurrent thrombotic events.
• Two patients (in the HIT group) developed major bleeding, necessitating anticoagulation discontinuation.
• Sixteen patients received apixaban (70%), and seven received rivaroxaban (30%).

Conclusions:

• Apixaban and rivaroxaban appear to be safe and effective anticoagulants in this small cohort of patients with HIT and APS.
• DOACs represent a viable treatment option for patients with HIT or APS who cannot tolerate, fail, or refuse warfarin.
• Individualized treatment decisions are recommended based on patient-specific factors.